Standout Papers
- Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 (2019)
- Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study (2020)
Citation Impact
3 from Science/Nature 52 standout
Citing Papers
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Principles and therapeutic applications of adaptive immunity
2024 Standout
Works of A. Shaw being referenced
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
2020 Standout
Mediators of inflammation and bone remodeling in rheumatic disease
2015
Author Peers
| Author | PRM | Oncology | Molecular Biology | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|
| A. Shaw | 762 | 612 | 372 | 17 | 1.1k | |
| Anthony P. Cheung | 16 | 38 | 226 | 60 | 1.9k | |
| Horst Lohnstein | 9 | 17 | ||||
| Claus Ballegaard Nielsen | 2 | 182 | ||||
| A.‐C. Salomonsson | 8 | 5 | 18 | 9 | 315 | |
| Ingo Lieb | 5 | 26 | 394 |
All Works
Login with ORCID to disown or claim papers
Loading papers...